Program
EV71
A development code. Also written as “EV71 vaccine”, “EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose)” and “EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose)”.
Its studies are mostly in Hand, Foot and Mouth Disease · Enterovirus Infections · Infections, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sinovac Biotech | 141 open or running | phase 4since Sep 4, 2017 | Jan 7, 2011 | Jan 9, 2027NCT07793175 |
| Enimmune | 30 open or running | phase 3since Oct 18, 2021 | May 16, 2016 | none ahead |
| Sinopharm | 10 open or running | phase 4since Sep 15, 2019 | Sep 15, 2019 | none ahead |
Also a collaborator on its studies: changchun-institute-of-biological-products-co-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Jan 7, 2011.
- Jan 2, 2012Phase 3 study in Hand, Foot and Mouth DiseaseSinovac Biotech · NCT01507857 · 10,077 enrolled · China
- Jul 5, 2012Phase 3 study in Hand, Foot and Mouth DiseaseSinovac Biotech · NCT01636245 · 1,400 enrolled · China
- Mar 13, 2013Phase 2 study in InfectionsSinovac Biotech · NCT01812135 · China
- May 16, 2016Enimmune's first study: phase 2 study in Enterovirus InfectionsNew to EnimmuneEnimmune · NCT02777411 · 122 enrolled · Taiwan
- Aug 4, 2016Phase 2 study in Enterovirus InfectionsEnimmune · NCT03268083 · 140 enrolled · Taiwan
- Sep 4, 20172 phase 4 studies in Hand, Foot and Mouth DiseaseSinovac Biotech · NCT03274102, NCT03278132
- Mar 2, 2019Phase 4 study in Hand, Foot and Mouth DiseaseSinovac Biotech · NCT03873740 · 300 enrolled · China
- Mar 29, 2019Phase 3 study in Hand, Foot and Mouth DiseaseSinovac Biotech · NCT03909074 · 900 enrolled · China
- Sep 15, 2019Sinopharm's first study: phase 4 study in Enterovirus InfectionsNew to SinopharmSinopharm · NCT04091880 · 1,134 enrolled · China
- Oct 18, 2021Phase 3 study in Enterovirus InfectionsEnimmune · NCT05099029 · 3,982 enrolled · Taiwan, Vietnam
- Sep 15, 2023Phase 2 study in Hand, Foot and Mouth DiseaseSinovac Biotech · NCT06063057 · 744 enrolled · China
- Dec 22, 2024Phase 2 study in Hand, Foot and Mouth DiseaseSinovac Biotech · NCT06754384 · 552 enrolled · China
- Jun 10, 2025Phase 4 study in EV71 VaccineSinovac Biotech · NCT07026500 · 720 enrolled · China
- Aug 25, 2026No phase study in Hand, Foot and Mouth DiseaseSinovac Biotech · NCT07793175 · 320 planned · Vietnam
Ahead
- Jan 9, 2027Primary completion: no phase study in Hand, Foot and Mouth DiseaseSinovac Biotech · NCT07793175
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07793175Hand, Foot and Mouth Disease · Vietnam | – | Not yet recruiting | Sinovac Biotech | Jan 9, 2027 | 320 |
| NCT07026500EV71 Vaccine · China | 4 | Completed | Sinovac Biotech | Apr 30, 2020 | 720 |
| NCT06754384Hand, Foot and Mouth Disease · China | 2 | Completed | Sinovac Biotech | Dec 30, 2025 | 552 |
| NCT06063057Hand, Foot and Mouth Disease · China | 2 | Completed | Sinovac Biotech | Dec 19, 2025 | 744 |
| NCT05099029Enterovirus Infections · Taiwan, Vietnam | 3 | Completed | Enimmune | Jul 31, 2024 | 3,982 |
| NCT04091880Enterovirus Infections · China | 4 | Completed | Sinopharm | Jan 6, 2020 | 1,134 |
| NCT03909074Hand, Foot and Mouth Disease · China | 3 | Completed | Sinovac Biotech | Jun 17, 2019 | 900 |
| NCT03873740Hand, Foot and Mouth Disease · China | 4 | Completed | Sinovac Biotech | Jan 21, 2019 | 300 |
| NCT03278132Hand, Foot and Mouth Disease · China | 4 | Completed | Sinovac Biotech | Sep 15, 2017 | 120 |
| NCT03274102Hand, Foot and Mouth Disease · China | 4 | Completed | Sinovac Biotech | Nov 1, 2017 | 780 |
| NCT03268083Enterovirus Infections · Taiwan | 2 | Completed | Enimmune | Aug 2017 | 140 |
| NCT02777411Enterovirus Infections · Taiwan | 2 | Completed | Enimmune | Jan 2016 | 122 |
| NCT01812135Infections · China | 2 | Withdrawn | Sinovac Biotech | Nov 2011 | 0 |
| NCT01636245Hand, Foot and Mouth Disease · China | 3 | Completed | Sinovac Biotech | Sep 2012 | 1,400 |
| NCT01507857Hand, Foot and Mouth Disease · China | 3 | Completed | Sinovac Biotech | Mar 2013 | 10,077 |
| NCT01421121Infections · China | 2 | Completed | Sinovac Biotech | Sep 2011 | 540 |
| NCT01273246Hand, Foot and Mouth Disease · China | 1 | Completed | Sinovac Biotech | Jun 2011 | 132 |
| NCT01273233Infections · China | 1 | Completed | Sinovac Biotech | Feb 2011 | 36 |
How it is read
Names in the registry
- “EV71 vaccine”, 3 entries
- “EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose)”, 2 entries
- “EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose)”, 2 entries
- “Enterovirus type EV71 vaccine (Vero cell), Inactivated”, 1 entry
- “EV71 inactivated enterovirus vaccine (Vero cell) )(for ages 6-71 months)”, 1 entry
Codes read as this program: ENTEROVIRUS71VACCINE, EV71.
Conditions, from the studies’ own filings
- Hand, Foot and Mouth Disease, 11 studies
- Enterovirus Infections, 4 studies
- Infections, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.